A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.

@article{Lim2007API,
  title={A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.},
  author={Soon-Thye Lim and Luis E. Fayad and Anil Tulpule and Manuel R. Modiano and Fernando Cabanillas and Bernard Laffranchi and Cecilia Allievi and Alberto Bernareggi and Alan Mitchell Levine},
  journal={Leukemia & lymphoma},
  year={2007},
  volume={48 2},
  pages={
          374-80
        }
}
The purpose of the study was to evaluate the safety, efficacy, and pharmacokinetics of pixantrone (BBR2778) when substituted for etoposide in the ESHAP regimen in patients with aggressive relapsed or refractory non-Hodgkin's lymphoma. Nineteen patients received protocol therapy, consisting of pixantrone 80 mg/m2 over 1 h on day 1, methylprednisolone 500 mg on days 1 - 5, cisplatin 25 mg/m2 on days 1 - 4, and cytarabine 2000 mg/m2 on day 5. Cycles were repeated every 21 days, in the outpatient… CONTINUE READING
BETA

Citations

Publications citing this paper.

Similar Papers